Search
Search Constraints
You searched for: Author/Creator Burmester, G RLimit your search
- Burmester, G R [remove] 42
- 616.723005 42
- Rheumatism -- Periodicals 42
- TNF blocking -- RA -- psoriatic arthritis -- ankylosing spondylitis -- inflammation -- immunity -- IL-1ra -- guideline 2
- ACR, American College of Rheumatology -- AEs, adverse events -- ANAs, antinuclear antibodies -- ANCOVA, analysis of covariance -- CRP, C reactive protein -- CTC, Common Toxicity Criteria -- DAS, disease activity score -- DMARDs, disease modifying antirheumatic drugs -- dsDNA, double stranded DNA -- ESR, erythrocyte sedimentation rate -- HAQ, Health Assessment Questionnaire -- ITT, intention to treat -- MTX, methotrexate -- NSAIDs, non-steroidal anti-inflammatory drugs -- RA, rheumatoid arthritis -- sc, subcutaneously -- SJC, swollen joint count -- TJC, tender joint count -- TNFα, tumour necrosis factor α 1
- ACR, American College of Rheumatology -- AS, ankylosing spondylitis -- CHF, congestive heart failure -- DAS, Disease Activity Score -- DMARD, disease modifying antirheumatic drug -- HAQ-DI, Health Assessment Questionnaire disability index -- MTX, methotrexate -- PsA, psoriatic arthritis -- RA, rheumatoid arthritis -- SF-36, Medical Outcome Survey Short Form 36 -- TNF, tumour necrosis factor -- VAS, visual analogue scale 1
- ACR, American College of Rheumatology -- CRP, C reactive protein -- 3D, three dimensional -- DIP, distal interphalangeal -- DMARDs, disease modifying antirheumatic drugs -- ESR, erythrocyte sedimentation rate -- IV, intravenous -- MCP, metacarpophalangeal -- MIP, maximum intensity projection -- MRI, magnetic resonance imaging -- PIP, proximal interphalangeal -- RA, rheumatoid arthritis -- RF, rheumatoid factor -- US, ultrasonography 1
- ACR, American College of Rheumatology -- SCDAI, Simplified composite Disease Activity Index -- DAS28, 28-joint Disease Activity Score -- DMARD, disease-modifying antirheumatic drug -- HACA, human antichimeric antibody -- MTX, methotrexate -- SDAI, simplified Disease Activity Index -- TNF, tumour necrosis factor 1
- AE, adverse event -- CDC, Centers for Disease Control -- CHF, congestive heart failure -- DMARD, disease modifying antirheumatic drug -- E/100 PYs, events per 100 patient-years -- FDA, Food and Drug Administration -- LTB, latent TB -- MTX, methotrexate -- OLE, open label extension trial -- PY, patient-year -- RA, rheumatoid arthritis -- RCT, randomised controlled trial -- SAE, serious adverse event -- SEER, Surveillance, Epidemiology and End Results -- SIR, standardised incidence ratio -- SLE, systemic lupus erythematosus -- TB, tuberculosis -- TNF, tumour necrosis factor -- TST, tuberculin skin test 1
- AIA, adjuvant induced arthritis -- ARNT, aryl hydrocarbon receptor nuclear translocator -- bHLH, basic helix-loop-helix -- CIA, collagen induced arthritis -- COX-2, cyclo-oxygenase-2 -- CTAD, C-terminal transactivation domain -- CTL, cytotoxic T lymphocyte -- EC, endothelial cells -- EPO, erythropoietin -- FIH, factor inhibiting HIF-1 -- HIF, hypoxia inducible factor -- HSP, heat shock protein -- IL, interleukin -- MAPK, mitogen activated protein kinase -- MMP, matrix metalloproteinase -- ODD, oxygen dependent degradation domain -- PHD, prolyl hydroxylase domain-containing protein -- PI3K, phosphatidylinositol 3-kinase -- pVHL, von Hippel-Lindau tumour suppressor protein -- RA, rheumatoid arthritis -- ROS/RNS, reactive oxygen and nitrogen species -- SDF-1, stromal cell derived factor 1 -- TNFα, tumour necrosis factor α -- VEGF, vascular endothelial growth factor 1
- AUC, area under the curve -- CE, clinical examination -- CSS, clinical synovitis score(s) -- MRI, magnetic resonance imaging -- PIP, proximal interphalangeal -- RA, rheumatoid arthritis -- ROC, receiver operating characteristic -- SLOT, sagittal laser optical tomography -- US, ultrasound -- USS, ultrasound score(s) 1